Top Software Tools for Performing Time-to-Event Analyses in Clinical Trials

Time-to-event analysis, often referred to as survival analysis, is a fundamental statistical method in clinical trials, especially in fields like oncology, cardiology, and infectious disease. Whether assessing Overall Survival (OS), Progression-Free Survival (PFS), or Time to Progression (TTP), professionals rely on robust software tools to conduct accurate and reproducible analyses. Choosing the right software is essential for regulatory compliance, reproducibility, and efficient trial decision-making.

This guide outlines the leading software platforms used for time-to-event analyses, including their strengths, typical applications, and how they support statistical requirements in clinical research. Each tool is widely used in pharma biostatistics teams and aligns with best practices encouraged by agencies such as the USFDA.

Why Software Selection Matters for Time-to-Event Analysis

Time-to-event data is unique due to censoring, variable follow-up times, and the need for visual survival curves. The right software can:

• Efficiently handle right-censored data
• Generate Kaplan-Meier (KM) plots
• Estimate hazard ratios via Cox proportional hazards models
• Conduct log-rank tests and stratified analyses
• Support interim survival analysis protocols

Proper software use also supports pharma validation requirements for reproducibility and data traceability.

1. R: The Open-Source Powerhouse

Best for: Flexibility, advanced modeling, reproducibility

• Key packages: survival, survminer, rms
• Functions for Kaplan-Meier estimation, Cox models, parametric survival models
• Highly customizable survival plots
• Integrated with markdown for report generation

R is widely adopted by statisticians and academic researchers and is ideal for data exploration, simulation, and regulatory reports. Use ggsurvplot() from survminer for polished survival visualizations, commonly seen in stability study reports and oncology submissions.

2. SAS: Industry Standard for Clinical Submissions

Best for: Regulatory trials, standardization, large datasets

• Procedures: PROC LIFETEST, PROC PHREG
• Built-in support for Kaplan-Meier, log-rank test, Cox models
• Preferred by CROs and large pharma for FDA/EMA submissions
• Compatible with CDISC/ADaM datasets

SAS is indispensable for compliant trial environments where outputs must meet strict formatting and validation standards. Many pharma SOPs mandate SAS for primary analysis datasets.

3. STATA: User-Friendly with Powerful Survival Tools

Best for: Quick model fitting, intuitive syntax

• Commands: stset, sts, stcox
• Easy handling of time-varying covariates
• Graphical KM curves with automatic risk tables
• Well-documented output with hazard ratios and p-values

STATA is often used in academic clinical research centers and hybrid data teams. Its blend of command-line power and GUI options makes it a favorite for biostatisticians at all levels.

4. Python (Lifelines Package): Ideal for Data Science Integration

Best for: Tech-savvy teams, automation, integration with machine learning

• Popular library: lifelines
• Functions: KaplanMeierFitter, CoxPHFitter
• Seamless with Pandas and NumPy dataframes
• Compatible with Jupyter Notebooks for exploratory survival modeling

Python is emerging in pharma analytics for reproducible pipelines, adaptive designs, and digital health trials. While not yet a regulatory mainstay, it’s excellent for innovation and secondary analyses.

5. SPSS: Accessible but Limited

Best for: Basic analyses, educational environments

• Menus for Kaplan-Meier, log-rank, Cox regression
• No coding required—ideal for non-programming users
• Limited flexibility in advanced modeling or scripting

SPSS is suitable for introductory trial design teams or those focused on smaller datasets. It is not generally used in large-scale or regulatory-facing studies.

Software Feature Comparison

Best Practices When Using Software for Survival Analysis

1. Always predefine your analysis plan in the SAP
2. Use validated software as per company policy
3. Check proportional hazards assumption in Cox models
4. Include censoring indicators in Kaplan-Meier plots
5. Document version numbers and output formats for audit purposes
6. Link outputs with Stability Studies or trial documentation systems

Regulatory Guidance on Software Use

While no specific software is mandated, regulatory bodies expect transparency, reproducibility, and traceability. Adherence to ICH E9 and ICH E3 standards is critical when submitting survival analyses, especially in adaptive or event-driven designs.

In practice, R and SAS remain the most accepted for formal submissions, while STATA and Python complement exploratory work. Always pair your software with compliant GMP documentation.

Conclusion: Match the Tool to Your Trial’s Needs

Time-to-event analyses are integral to modern clinical trials, and selecting the right software ensures robust, defensible results. From R’s open-source flexibility to SAS’s regulatory muscle and Python’s modern workflows, there’s a tool for every stage of survival analysis. Understand your protocol, regulatory goals, and team’s technical capability to make the optimal choice.

Best Software Tools for Time-to-Event Analyses in Clinical Trials

Time-to-event (TTE) analysis—commonly used to evaluate survival, disease progression, or treatment failure—is a cornerstone of clinical trials, especially in oncology and chronic disease studies. Robust software tools are essential for implementing survival analysis techniques like Kaplan-Meier estimation, log-rank tests, and Cox proportional hazards models. This guide highlights the most widely used and validated software solutions for survival analysis in pharmaceutical settings.

Whether you are part of a biostatistics team, clinical data group, or regulatory submission unit, choosing the right tool is critical to accuracy, compliance, and effective communication. This tutorial provides a comparative overview of the top platforms, their strengths, and recommended use cases in alignment with CDSCO and USFDA expectations.

Key Requirements for Survival Analysis Software

• Validated and audit-ready per 21 CFR Part 11
• Ability to handle censored data
• Built-in functions for Kaplan-Meier, log-rank, and Cox regression
• Support for graphical outputs (survival curves, forest plots)
• Reproducible code or audit trail
• Integration with CDISC standards and submission formats

All tools should support compliant workflows and standardized reporting, aligning with Pharma SOP documentation for statistical processes.

1. R and the ‘survival’ Package

Overview: R is an open-source statistical programming language widely used for clinical trial analysis. The survival package is its cornerstone for TTE analysis.

Key Functions:

• survfit(): Kaplan-Meier estimation
• coxph(): Cox proportional hazards modeling
• survdiff(): Log-rank test
• ggsurvplot(): Enhanced visualization using ‘survminer’

R allows complete control over data and graphical output, making it ideal for publications, regulatory appendices, and internal reports. However, validation and version control are required for compliant use in GxP environments.

2. SAS (Statistical Analysis System)

Overview: SAS is a gold-standard commercial tool in the pharmaceutical industry, offering strong validation, audit trails, and regulatory acceptance.

Key Procedures:

• PROC LIFETEST: Kaplan-Meier and log-rank test
• PROC PHREG: Cox regression
• ODS Graphics: Automated KM curve generation

SAS is especially preferred for its integration with CDISC/ADaM datasets and seamless export to submission formats. It supports stability study tracking through macro-driven automation.

3. STATA

Overview: STATA offers a GUI-based and command-line interface with powerful survival analysis capabilities, commonly used in academic and international trials.

Key Functions:

• sts graph: Kaplan-Meier plots
• stcox: Cox regression
• stcurve: Custom survival curve generation
• Supports time-varying covariates and stratified models

STATA is ideal for exploratory work and mixed-model survival analysis. Its graphical outputs are high quality and journal-ready.

4. SPSS (Statistical Package for the Social Sciences)

Overview: While less common in regulatory trials, SPSS remains a user-friendly option for early-phase or academic research in survival analysis.

Key Features:

• KM survival curves with click-based customization
• Cox regression via GUI or syntax
• Good for training and teaching environments

SPSS is best suited for smaller trials or institutions that need quick exploratory insights without the complexity of full coding.

5. Python and the ‘lifelines’ Package

Overview: Python is gaining traction in clinical research. The lifelines package enables full survival modeling with elegant syntax and rich visualization.

Highlights:

• KaplanMeierFitter(): KM estimation
• CoxPHFitter(): Proportional hazards model
• Integrated plotting via Matplotlib
• Great for automation and reproducibility in modern workflows

Python is useful for algorithm-driven studies and automation, especially when paired with pharma validation tools for script certification.

Comparison Table

Best Practices When Using Survival Tools

1. Pre-define survival endpoints and censoring rules in SAP
2. Use validated software per regulatory requirements
3. Maintain audit trails and version control for scripts
4. Annotate Kaplan-Meier curves with number-at-risk and medians
5. Use appropriate tools for Cox assumption testing
6. Embed outputs into CSR and GMP documentation

Regulatory Submission Considerations

When using any of these tools for clinical trial data analysis:

• Ensure output files are traceable and reproducible
• Provide scripts or macros in submission datasets (per ICH E3 and E9)
• Align outputs with ADaM data structures for survival (e.g., ADSL and ADTTE)
• Document software versions and libraries used

Conclusion: Choose the Right Tool for the Right Analysis

Time-to-event analyses demand precision, transparency, and regulatory readiness. From the flexibility of R and Python to the robustness of SAS and STATA, selecting the right survival analysis software is a strategic decision. Each platform brings unique benefits, and your choice should reflect the trial phase, submission needs, and internal validation capacity. By aligning tools with SOPs, statistical plans, and regulatory frameworks, pharma professionals can ensure survival analysis supports both scientific insight and approval success.

Kaplan-Meier Curves and Estimating Median Survival in Clinical Trials

Survival analysis is crucial in clinical research, particularly when evaluating time-dependent outcomes like disease progression, recurrence, or death. Among its core techniques, Kaplan-Meier (KM) curves are the most widely used method to estimate survival probability over time. These curves allow researchers and regulators to visualize survival distributions and determine key metrics like the median survival time.

This tutorial offers a step-by-step guide to Kaplan-Meier curve construction, interpretation, and the estimation of median survival in the context of clinical trials. It is designed for pharma and clinical professionals seeking to strengthen their grasp of time-to-event analysis while ensuring compliance with statistical and regulatory guidelines such as those outlined by the USFDA.

What Is a Kaplan-Meier Curve?

A Kaplan-Meier curve is a step-function graph that estimates the survival function from time-to-event data. It shows the probability of surviving beyond certain time points in the presence of censored data.

The KM method allows for real-time survival analysis even when participants drop out or the trial ends before an event occurs. This flexibility makes it indispensable for studies where not all subjects reach an endpoint during the trial period.

Components of a Kaplan-Meier Curve

• X-axis: Time since the start of the study (e.g., days, weeks, months)
• Y-axis: Estimated survival probability
• Steps: Represent event occurrences (e.g., death, progression)
• Tick marks: Indicate censored data points
• Risk table: Number of patients at risk at different time points (often included below the graph)

Key Concepts for Estimation

1. Survival Probability (S(t))

The probability that a patient survives longer than a specific time t. This is recalculated at each time point when an event occurs.

2. Censoring

Occurs when a participant exits the trial (lost to follow-up, study end) before experiencing the event. Kaplan-Meier accommodates right censoring without introducing bias.

3. Median Survival Time

The time at which 50% of the study population is expected to have experienced the event. This is found by identifying the point where the survival curve drops below 0.5 on the Y-axis.

Constructing a Kaplan-Meier Curve: Step-by-Step

1. Sort data: Order participants by the time to event or censoring.
2. Calculate risk set: Number of patients still at risk at each time point.
3. Calculate survival probability: Use the formula S(t) = S(t−1) × (1 − d/n) where d = events, n = individuals at risk.
4. Plot curve: Each event causes a downward step in the curve.
5. Mark censored observations: Use tick marks on the curve to show censored data.

Example Application: Oncology Trial

In a Phase III oncology trial comparing Drug A vs. placebo, survival data showed that the median overall survival (OS) for Drug A was 12.4 months compared to 9.8 months for placebo. Kaplan-Meier curves visually represented the survival advantage, and the log-rank test confirmed statistical significance.

This visualization allowed regulatory agencies to easily interpret survival benefit and contributed to the eventual approval of Drug A for this indication.

Interpreting Kaplan-Meier Curves

Proper interpretation of KM curves includes:

• Vertical drops: Represent event occurrences.
• Plateaus: Periods without events.
• Censored tick marks: Subjects no longer contributing to risk.
• Median survival: Time at which the curve crosses 0.5.
• Confidence intervals: Visualize uncertainty around estimates (often shaded areas or dashed lines).

Statistical Comparison Between Groups

To compare Kaplan-Meier curves between treatment groups:

1. Log-Rank Test

• Tests the null hypothesis that there’s no difference between groups.
• Assumes proportional hazards over time.

2. Cox Proportional Hazards Model

• Provides hazard ratios (HR) with 95% confidence intervals.
• Adjusts for covariates (age, sex, disease severity).

Best Practices in Kaplan-Meier Analysis

1. Define event and censoring criteria clearly in the protocol and SAP.
2. Ensure consistent time origin (e.g., date of randomization).
3. Use software like R (survival package), SAS (PROC LIFETEST), or SPSS for accurate estimation.
4. Always include confidence intervals and risk tables in reports.
5. Align plotting and reporting standards with regulatory expectations from CDSCO and StabilityStudies.in.

Software Tools for Kaplan-Meier Estimation

• R: survival and survminer for estimation and visualization
• SAS: PROC LIFETEST and PROC PHREG
• STATA, Python: Lifelines and other libraries
• SPSS: Kaplan-Meier Estimation module

Regulatory Expectations for KM Plots

Agencies like the EMA expect KM curves to be:

• Accompanied by a full SAP explanation
• Displayed in CSR (Clinical Study Report)
• Provided with digital source data for reproducibility
• Used in both interim and final analyses with consistency

Common Pitfalls to Avoid

• Failing to properly mark censored data
• Over-interpreting differences without statistical testing
• Incorrect time origin assignment
• Plotting survival beyond the last event time

Conclusion: Kaplan-Meier Curves Empower Clinical Decision-Making

Kaplan-Meier analysis provides a powerful visualization of survival trends in clinical trials. From estimating median survival to comparing treatment arms, KM curves offer actionable insights when executed correctly. Pharma professionals, statisticians, and regulatory experts must master the generation and interpretation of these curves to support successful trial design, execution, and submission.